Parkinson’s Disease – Landscape & Forecast – Disease Landscape & Forecast

Ten new brands entered the Parkinson’s disease (PD) market over the last decade (e.g., Acorda’s Inbrija, Sunovion’s Kynmobi, Neurocrine’s Ongentys), and additional new options are advancing, including three continuously delivered, subcutaneous pumps (i.e., AbbVie’s foslevodopa / foscarbidopa [Vyalev / Produodopa], NeuroDerm / Mitsubishi Tanabe’s levodopa / carbidopa [ND0612], and Supernus’s apomorphine [SPN-830]) and an extended-release levodopa agent (i.e., Amneal’s IPX203). These later therapies have the potential to significantly alter treatment approaches for the most vulnerable PD patients. The mid-phase pipeline is large and diverse and includes novel symptomatic (e.g., motor and nonmotor) therapies and potentially disease-modifying agents. As developers seek to establish a niche for their products, the treatment algorithm will become more complex. Although new brands can drive market value, intense competition, coupled with patient and payer cost sensitivity in a crowded and mostly generic market, creates a challenging launch environment. Generic options are available in every PD drug class, and brands entering these classes will struggle to compete without decisive clinical differentiation. A deep understanding of current and future market dynamics in PD will be critical for new and established players vying for a share of this increasingly competitive landscape.

Questions answered:

  • What will be the clinical and commercial impact of emerging levodopa reformulations (i.e., Vyalev / Produodopa, ND-0612, and IPX203)?
  • How do neurologists view the clinical prospects for emerging adjunctive therapies for motor fluctuations, dyskinesia, and dementia?
  • Which putative disease-modifying therapies are most promising?
  • How will neurologists adopt the new acute rescue therapies for “off” periods, and which unmet needs remain for other novel therapies targeting motor symptoms in PD?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed and drug-treated prevalent cases of PD by country.

Emerging therapies: Phase 2: 18 drugs; Phase 3: 2 drugs; preregistration: 2 drugs.

Market forecast features: 10-year, annualized, drug-level sales and patient shares of key PD therapies through 2032, segmented by brands / generics.

Key companies: AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics, Adamas Pharmaceuticals, Amneal Pharmaceuticals, Cerevel Therapeutics, Eisai, Hisamitsu Pharmaceutical, Kyowa Kirin, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Newron Pharmaceuticals, NeuroDerm, Osmotica Pharmaceuticals, Pharma Two B, Sumitomo Dainippon Pharma, Sunovion, Supernus, Takeda, Teva, UCB, Zambon Pharma.

Key drugs: levodopa, amantadine, apomorphine, Duodopa / Duopa, entacapone, Gocovri, Haruropi Tape, Inbrija, IPX203, Kynmobi, Lecigon, ND0612, Neupro, Nourianz, Nuplazid, Ongentys, Osmolex ER, pramipexole, P2B001, rasagiline, ropinirole, Rytary, selegiline, tavapadon, Trerief, Vyalev, Xadago.

Solution enhancement:

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents